Clinical Trial Update: Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) [Phase 4]

View source ↗

Summary

Open-label Phase 4 neoadjuvant trial update evaluating Ontruzant (SB3) in HER2-positive early breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Neoplasms

Drugs mentioned

• ONTRUZANT (TRASTUZUMAB)

Snippet

Sponsor: Institut fuer Frauengesundheit | Conditions: Breast Cancer, Breast Neoplasms | Phase 4 | Status: UNKNOWN